Privigen FDA Approval History
FDA Approved: Yes (First approved July 26, 2007)
Brand name: Privigen
Generic name: immune globulin intravenous (human)
Dosage form: Liquid
Company: CSL Behring
Treatment for: Primary Immunodeficiency Syndrome, Idiopathic Thrombocytopenic Purpura, Chronic Inflammatory Demyelinating Polyradiculoneuropathy
Privigen is an immune globulin intravenous (human), 10% liquid indicated for the treatment of primary humoral immunodeficiency (PI), chronic immune thrombocytopenic purpura (ITP), and chronic inflammatory demyelinating polyneuropathy (CIDP).
Development timeline for Privigen
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.